Zealand Pharma revenue and financials
kr 265.60Change from previous close: −0.11%Absolute change: −kr 0.30
In the fiscal year ended December 2025, Zealand Pharma reported revenue of kr 9.21B (+14,598.86% year over year). Net income was kr 6.46B, a net margin of 70.0%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +14,598.86%
- 2025 vs 2024
- Net margin
- 70.0%
- 2024: -1,720.9%
Financial data
Amounts in millions of DKK; per-share values in DKK; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | 9,215 | 62.7 | 343 | 104 | — |
| Cost of revenue | 0.8 | 7.9 | 19.2 | 0.0 | — |
| Gross profit | 9,214 | 54.8 | 324 | 104 | — |
| Selling, general and administrative | 273 | 229 | 89.8 | 307 | — |
| Research and development | 1,605 | 920 | 685 | 614 | — |
| Operating income | 7,114 | -1,269 | -577 | -817 | — |
| EBIT | 7,030 | -1,049 | -683 | -916 | — |
| EBITDA | 7,057 | -1,024 | -658 | -798 | — |
| Interest expense | 29.1 | 34.0 | 25.8 | 56.5 | — |
| Pre-tax income | 7,001 | -1,083 | -709 | -972 | — |
| Income tax | 546 | -4.6 | -5.1 | -6.4 | — |
| Net income | 6,455 | -1,079 | -704 | -1,202 | — |
| Net income to common shareholders | 6,455 | -1,079 | -704 | -1,202 | — |
| Basic EPS | 91.56 | -16.24 | -12.44 | -26.02 | — |
| Diluted EPS | 90.22 | -16.24 | -12.44 | -26.02 | — |
| Average shares (basic) | 70.5 | 66.4 | 56.6 | 46.2 | — |
| Average shares (diluted) | 71.5 | 66.4 | 56.6 | 46.2 | — |